{"artifactReference":{"display":"Critically appraised summary of all-cause mortality in meta-analysis of RCTs of heparin for moderately ill patients with COVID-19","reference":"Evidence/18812","type":"Evidence"},"content":[{"author":{"display":"Brian S. Alper"},"classifier":[{"coding":[{"code":"very-low","display":"Very low quality","system":"http://hl7.org/fhir/certainty-rating"}]}],"component":[{"author":{"display":"Brian S. Alper"},"classifier":[{"coding":[{"code":"serious-concern","display":"serious concern","system":"http://hl7.org/fhir/certainty-rating"}]}],"informationType":"rating","summary":"risk of bias in both included trials","type":{"coding":[{"code":"RiskOfBias","display":"Risk of bias","system":"http://hl7.org/fhir/certainty-type"}]}},{"author":{"display":"Brian S. Alper"},"classifier":[{"coding":[{"code":"serious-concern","display":"serious concern","system":"http://hl7.org/fhir/certainty-rating"}]}],"informationType":"rating","summary":"high degree of heterogeneity (I-squared 80.7%) with confidence intervals of 2 trial effect estimates barely overlapping","type":{"coding":[{"code":"Inconsistency","display":"Inconsistency","system":"http://hl7.org/fhir/certainty-type"}]}},{"author":{"display":"Brian S. Alper"},"classifier":[{"coding":[{"code":"no-concern","display":"no serious concern","system":"http://hl7.org/fhir/certainty-rating"}]}],"informationType":"rating","type":{"coding":[{"code":"Indirectness","display":"Indirectness","system":"http://hl7.org/fhir/certainty-type"}]}},{"author":{"display":"Brian S. Alper"},"classifier":[{"coding":[{"code":"serious-concern","display":"serious concern","system":"http://hl7.org/fhir/certainty-rating"}]}],"informationType":"rating","summary":"95% confidence interval includes both large effects and no effects","type":{"coding":[{"code":"Imprecision","display":"Imprecision","system":"http://hl7.org/fhir/certainty-type"}]}},{"author":{"display":"Brian S. Alper"},"classifier":[{"coding":[{"code":"no-concern","display":"no serious concern","system":"http://hl7.org/fhir/certainty-rating"}]}],"informationType":"rating","type":{"coding":[{"code":"PublicationBias","display":"Publication bias","system":"http://hl7.org/fhir/certainty-type"}]}}],"freeToShare":true,"informationType":"rating","summary":"serious concerns with risk of bias, inconsistency, and imprecision","type":{"coding":[{"code":"Overall","display":"Overall certainty","system":"http://hl7.org/fhir/certainty-type"}]}}],"copyright":"https://creativecommons.org/licenses/by-nc-sa/4.0/","date":"2021-11-02T14:48:59.890Z","id":"example-certainty-rating","identifier":[{"assigner":{"display":"Computable Publishing LLC"},"system":"https://fevir.net","type":{"text":"FEvIR Object Identifier"},"value":"27756"}],"resourceType":"ArtifactAssessment","text":{"div":"

Generated Narrative: ArtifactAssessment

Resource ArtifactAssessment "example-certainty-rating"

identifier: FEvIR Object Identifier:\u00a027756

date: 2021-11-02T14:48:59.89Z

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

artifact: Evidence/18812: Critically appraised summary of all-cause mortality in meta-analysis of RCTs of heparin for moderately ill patients with COVID-19

content

informationType: rating

summary: serious concerns with risk of bias, inconsistency, and imprecision

type: Overall certainty (Evidence Certainty Type#Overall)

classifier: Very low quality (Evidence Certainty Rating#very-low)

author: : Brian S. Alper

freeToShare: true

Components

-InformationTypeSummaryTypeClassifierAuthor
*ratingrisk of bias in both included trialsRisk of bias (Evidence Certainty Type#RiskOfBias)serious concern (Evidence Certainty Rating#serious-concern): Brian S. Alper
*ratinghigh degree of heterogeneity (I-squared 80.7%) with confidence intervals of 2 trial effect estimates barely overlappingInconsistency (Evidence Certainty Type#Inconsistency)serious concern (Evidence Certainty Rating#serious-concern): Brian S. Alper
*rating Indirectness (Evidence Certainty Type#Indirectness)no serious concern (Evidence Certainty Rating#no-concern): Brian S. Alper
*rating95% confidence interval includes both large effects and no effectsImprecision (Evidence Certainty Type#Imprecision)serious concern (Evidence Certainty Rating#serious-concern): Brian S. Alper
*rating Publication bias (Evidence Certainty Type#PublicationBias)no serious concern (Evidence Certainty Rating#no-concern): Brian S. Alper
","status":"generated"}}